Brief: Onxeo Q3 Revenues Reach 3.3 Million Euros

Valerio Therapeutics SA

25/10/2018 17:38

Oct 25 (Reuters) - ONXEO SA  C4X.PA :
    * FIRST SAFETY AND ACTIVITY RESULTS OF PHASE I DRIIV-1 STUDY
EXPECTED IN Q4 2018
    * PHASE IB/IIA COMBINATION STUDIES OF ASIDNA TO BE INITIATED
AS
EARLY AS H1 2019
    * CASH POSITION OF EUR 13 MILLION AT SEPTEMBER 30, 2018,
SUPPORTS
COMPANY'S DEVELOPMENT IN ATTRACTIVE FIELD OF DNA DAMAGE RESPONSE
INTO 2020
    * NEW FIRST-IN-CLASS COMPOUND FROM PLATON, EXPECTED BEFORE
END
2018, WILL ENTER PRECLINICAL TESTING IN 2019
    * PLATON: COMPANY INTENDS TO INITIATE PRECLINICAL STUDIES
AND CMC
ACTIVITIES FOR THIS NEW COMPOUND IN 2019
    * MAINTAINS OBJECTIVE TO ANNOUNCE NEW DRUG CANDIDATE, WITH
DIFFERENT TARGETS FROM THOSE OF ASIDNA, BY END OF 2018 IN ORDER
TO PROCEED WITH PRECLINICAL TESTS IN 2019
    * REVENUES FOR Q3 OF 2018 REACHED EUR 3.3 MILLION

Source text for Eikon:  ID:nBw9n0BWra 
Further company coverage:  C4X.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))